IMMUNOTHERAPY

In an interview with Targeted Oncology, Sattva S. Neelapu, MD, discussed the evolving role for CAR T-cell therapy in patients with B-cell lymphomas. He also highlighted the toxicities commonly associated with these therapies and how physicians can treat these AEs as they arise.

Ryan Weight, DO discusses takeaways from the Immuno-Oncology Institute Working Group Summit. The summit was a part of the Association of Community Cancer Centers’ Immuno-Oncology Institute and brought together multidisciplinary working groups to strategize policy and delivery changes for the effective use of immunotherapy.

The initial pilot study of CTL019 in heavily pretreated CD19-positive hematologic malignancies demonstrated the feasibility of CAR T-cell therapy in patients with CLL. A presentation at the 2019 American Society of Gene & Cell Therapy Annual Meeting reported 2 cases of chemotherapy-resistant CLL, with ongoing follow- up at 8 years showing persistence of CAR-engineered T cells and sustained remission, as determined by flow cytometry and deep sequencing of immunoglobulin H rearrangements. 

The American Society of Hematology has chosen Philip Greenberg, MD, to receive the 2019 E. Donnall Thomas Lecture and Prize for his work in immunotherapy.

In an interview with <em>Targeted Oncology</em>, Chong, a fellow at the University of Pennsylvania, discussed the 4-year follow-up data for CAR T cells in patients with DLBCL and FL. She also addressed the challenges that need to be overcome in order to give more patients access to this type of therapy.

In the phase I/II TRANSCEND CLL 004 study, chimeric antigen receptor T-cell therapy lisocabtagene maraleucel led to undetectable minimal residual disease in patients with relapsed/refractory chronic lymphocytic leukemia.

Kieron Dunleavy, MD, discussed current approaches to treating patients with MCL, highlighting peer discussions on the subject and information about the ZUMA-2 trial, in an interview with&nbsp;<em>Targeted Oncology</em>.

The FDA has granted an orphan drug designation to MB-102, a CD123-directed CAR T-cell therapy, for the treatment of patients with acute myeloid leukemia.

Updated results of the phase III KEYNOTE-048 trial comparing pembrolizumab as monotherapy and in combination with platinum chemotherapy and fluorouracil with standard-of-care chemotherapy support the use of the PD-1 inhibitor in&nbsp;the frontline for patients with recurrent or metastatic head and neck squamous cell carcinoma, according to Danny Rischin, MD, who presented the results of the final analysis at the 2019 American Society of Clinical Oncology Annual Meeting.

The development of an immune-related adverse event was associated with improved patient response in an FDA analysis of patients with advanced urothelial cancer treated with a PD-1/PD-L1 inhibitor.

The Cancer Research Institute announced 5 US scientists accepted into their inaugural CRI Lloyd J. Old STAR Program for taking on potentially transformative research in cancer immunology. The scientists were announced at the CRI&rsquo;s recent &ldquo;Immuno-Oncology: A Future Look&rdquo; event at the New York Academy of Sciences, which also recognized and celebrated the seventh annual Cancer Immunotherapy Month.

Significant activity was observed when ibrutinib was administered concurrently with CD19-directed CAR T-cell therapy compared with separately in patients with&nbsp;high-risk relapsed/refractory chronic lymphocytic leukemia who had progressed on or were intolerant of ibrutinib.&nbsp;Data presented at the 15th International Conference on Malignant Lymphoma show a high response rate with this concurrent treatment.&nbsp;

David Spigel, MD, chief scientific officer, Sarah Cannon Research Institute, discussed with&nbsp;<em>Targeted Oncology</em>at the 2019 ASCO Annual Meeting how the Association of Community Cancer Centers (ACCC) is the change agent for helping physicians provide their patients with quality care.&nbsp;<br /> &nbsp;

Jae H. Park, MD, discusses the current role and challenges in using CAR T-cell therapy in patients with relapsed or refractory acute myeloid leukemia. The 2 challenges now in this area are target selection and patient selection.

Announced at the 2019 ASCO Annual Meeting, the FDA is rolling out a pilot program that will provide more information and assistance for acquiring expanded access (EA) to investigational therapies for both oncologists and patients. The program is being called Project Facilitate.

Findings from a cohort of the&nbsp;phase II Targeted Agent and Profiling Utilization Registry (TAPUR) basket study revealed that heavily pretreated patients with&nbsp;metastatic breast cancer and high mutational burden benefited from pembrolizumab monotherapy.&nbsp;

Robert L. Ferris, MD, PhD, co-physician editor-in-chief, discusses the excitement of immunotherapy at the 2019 AACR Annual Meeting and how this research can inform resarch efforts moving forward.

The FDA has granted P-BCMA-101 with an orphan drug designation for the treatment of patients with relapsed and/or refractory multiple myeloma.

Findings from ongoing immunotherapy studies are expected to change the treatment paradigm in breast cancer as these agents become available to larger subsets of patients, according to Hope S. Rugo, MD, and Elizabeth A. Mittendorf, MD, PhD, who presented data at the 36th Annual Miami Breast Cancer Conference&reg;&nbsp;hosted by Physicians&rsquo; Education Resource&reg;, LLC.

Pembrolizumab&nbsp;(Keytruda) has received approval from the FDA&nbsp;in combination with axitinib (Inlyta) for the frontline treatment of patients with advanced renal cell carcinoma, based on phase III&nbsp; findings from the KEYNOTE-426 trial.

A discussion between&nbsp;regulators and special interest groups has cooled some of the excitement generated by the emergence of chimeric antigen receptor T-cell therapy for treating hematologic cancers.

Immune checkpoint inhibitors as monotherapy and in combinations regimens are producing promising efficacy data in metastatic head and neck cancers, depite struggles in finding the right treatment settings and patient population subsets.

Frederick L. Locke, MD, discusses how chimeric antigen receptor (CAR) T-cell therapies have evolved over the last 30 years of research in the field of hematologic malignancies.

The success of chimeric antigen receptor T-cell therapy observed in hematologic malignancies has not yet translated into the solid tumor setting; however, efforts continue to try to bring this new modality into the treatment paradigm for solid tumors, including pancreatic cancer.&nbsp;

In findings presented during the 2019 AACR Annual Meeting, safety and efficacy was seen with CAR T cells targeting&nbsp;mesothelin-expressing tumors&nbsp;in a preliminary clinical evaluation in patients with malignant pleural disease.

Susan Prockop, MD, discusses an option available for the treatment of central nervous Epstein-Barr virus-positive posttransplant lymphoproliferative disease.<br /> &nbsp;

Robert L. Ferris, MD, PhD, Co-Physician Editor in Chief, <em>Targeted Therapies in Oncology</em>,<em>&nbsp;</em>discusses<em>&nbsp;</em>the<em>&nbsp;</em>evolving<em>&nbsp;</em>role of immunotherapy in melanoma and non&ndash;small cell lung cancer, where by it is now the dominant therapeutic approach in these diseases in progressively earlier lines of therapy.

Less than 20% of healthcare providers feel very comfortable administering and prescribing appropriate and timely treatment to manage adverse events associated with immuno-oncology therapy, according to an independent needs assessment conducted by the ACCC IO Institute.

Consuming a diet rich in fiber could boost immunotherapy response in select patients with melanoma,&nbsp;according to early research findings.

Michael A. Postow, MD, shares advice to community oncologists on managing the side effects of immunotherapy in patients with melanoma.